vs
再生元制药（REGN）与RENAISSANCERE HOLDINGS LTD（RNR）财务数据对比。点击上方公司名可切换其他公司
再生元制药的季度营收约是RENAISSANCERE HOLDINGS LTD的1.6倍（$3.6B vs $2.2B），RENAISSANCERE HOLDINGS LTD净利率更高（23.5% vs 20.2%，领先3.3%），再生元制药同比增速更快（19.0% vs -36.8%），过去两年再生元制药的营收复合增速更高（0.8% vs -11.9%）
再生元制药是一家总部位于美国纽约州韦斯特切斯特县的生物技术企业，成立于1988年。公司最初围绕神经营养因子及其再生能力开展研究，这也是其名称的由来，后续业务逐步拓展至细胞因子与酪氨酸激酶受体领域，首款产品为VEGF陷阱类药物。
RenaissanceRe Holdings Ltd是总部位于百慕大的保险及相关商业服务提供商，核心业务覆盖再保险、常规保险两大板块，同时运营风险相关创新投资业务，为全球客户提供专业的风险对冲与保险解决方案。
REGN vs RNR — 直观对比
营收规模更大
REGN
是对方的1.6倍
$2.2B
营收增速更快
REGN
高出55.8%
-36.8%
净利率更高
RNR
高出3.3%
20.2%
两年增速更快
REGN
近两年复合增速
-11.9%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $3.6B | $2.2B |
| 净利润 | $727.0M | $515.8M |
| 毛利率 | 89.6% | — |
| 营业利润率 | 17.8% | — |
| 净利率 | 20.2% | 23.5% |
| 营收同比 | 19.0% | -36.8% |
| 净利润同比 | -10.1% | 72.6% |
| 每股收益（稀释后） | $6.75 | $6.57 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收REGNRNR
| Q1 26 | $3.6B | $2.2B | ||
| Q4 25 | $3.9B | $3.0B | ||
| Q3 25 | $3.8B | $3.2B | ||
| Q2 25 | $3.7B | $3.2B | ||
| Q1 25 | $3.0B | $3.5B | ||
| Q4 24 | $3.8B | $2.3B | ||
| Q3 24 | $3.7B | $4.0B | ||
| Q2 24 | $3.5B | $2.8B |
净利润REGNRNR
| Q1 26 | $727.0M | $515.8M | ||
| Q4 25 | $844.6M | $760.5M | ||
| Q3 25 | $1.5B | $916.5M | ||
| Q2 25 | $1.4B | $835.4M | ||
| Q1 25 | $808.7M | $170.0M | ||
| Q4 24 | $917.7M | $-189.7M | ||
| Q3 24 | $1.3B | $1.2B | ||
| Q2 24 | $1.4B | $503.9M |
毛利率REGNRNR
| Q1 26 | 89.6% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
营业利润率REGNRNR
| Q1 26 | 17.8% | — | ||
| Q4 25 | 22.7% | 42.5% | ||
| Q3 25 | 27.3% | 46.3% | ||
| Q2 25 | 29.4% | 41.8% | ||
| Q1 25 | 19.5% | -2.0% | ||
| Q4 24 | 26.1% | -3.6% | ||
| Q3 24 | 31.7% | 43.7% | ||
| Q2 24 | 30.2% | 25.0% |
净利率REGNRNR
| Q1 26 | 20.2% | 23.5% | ||
| Q4 25 | 21.7% | 25.6% | ||
| Q3 25 | 38.9% | 28.7% | ||
| Q2 25 | 37.9% | 26.1% | ||
| Q1 25 | 26.7% | 4.9% | ||
| Q4 24 | 24.2% | -8.3% | ||
| Q3 24 | 36.0% | 29.8% | ||
| Q2 24 | 40.4% | 17.8% |
每股收益（稀释后）REGNRNR
| Q1 26 | $6.75 | $6.57 | ||
| Q4 25 | $7.78 | $16.16 | ||
| Q3 25 | $13.62 | $19.40 | ||
| Q2 25 | $12.81 | $17.20 | ||
| Q1 25 | $7.27 | $3.27 | ||
| Q4 24 | $8.12 | $-3.76 | ||
| Q3 24 | $11.54 | $22.62 | ||
| Q2 24 | $12.41 | $9.41 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $1.6B |
| 总债务越低越好 | $2.0B | — |
| 股东权益账面价值 | $31.4B | $4.3B |
| 总资产 | $40.9B | $53.7B |
| 负债/权益比越低杠杆越低 | 0.06× | — |
8季度趋势，按日历期对齐
现金及短期投资REGNRNR
| Q1 26 | — | $1.6B | ||
| Q4 25 | $8.6B | $1.7B | ||
| Q3 25 | $8.4B | $1.7B | ||
| Q2 25 | $7.5B | $1.4B | ||
| Q1 25 | $8.3B | $1.6B | ||
| Q4 24 | $9.0B | $1.7B | ||
| Q3 24 | $9.8B | $1.6B | ||
| Q2 24 | $9.8B | $1.6B |
总债务REGNRNR
| Q1 26 | $2.0B | — | ||
| Q4 25 | — | $2.3B | ||
| Q3 25 | — | $2.2B | ||
| Q2 25 | — | $2.3B | ||
| Q1 25 | — | $2.8B | ||
| Q4 24 | — | $1.9B | ||
| Q3 24 | — | $1.9B | ||
| Q2 24 | — | $2.0B |
股东权益REGNRNR
| Q1 26 | $31.4B | $4.3B | ||
| Q4 25 | $31.3B | $11.6B | ||
| Q3 25 | $31.0B | $11.5B | ||
| Q2 25 | $29.9B | $10.8B | ||
| Q1 25 | $29.4B | $10.3B | ||
| Q4 24 | $29.4B | $10.6B | ||
| Q3 24 | $29.3B | $11.2B | ||
| Q2 24 | $28.2B | $10.2B |
总资产REGNRNR
| Q1 26 | $40.9B | $53.7B | ||
| Q4 25 | $40.6B | $53.8B | ||
| Q3 25 | $40.2B | $54.5B | ||
| Q2 25 | $38.2B | $54.7B | ||
| Q1 25 | $37.5B | $53.6B | ||
| Q4 24 | $37.8B | $50.7B | ||
| Q3 24 | $37.4B | $52.8B | ||
| Q2 24 | $36.1B | $51.6B |
负债/权益比REGNRNR
| Q1 26 | 0.06× | — | ||
| Q4 25 | — | 0.20× | ||
| Q3 25 | — | 0.19× | ||
| Q2 25 | — | 0.21× | ||
| Q1 25 | — | 0.27× | ||
| Q4 24 | — | 0.18× | ||
| Q3 24 | — | 0.17× | ||
| Q2 24 | — | 0.19× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.1B | — |
| 自由现金流经营现金流 - 资本支出 | $848.3M | — |
| 自由现金流率自由现金流/营收 | 23.5% | — |
| 资本支出强度资本支出/营收 | 6.4% | — |
| 现金转化率经营现金流/净利润 | 1.48× | — |
| 过去12个月自由现金流最近4个季度 | $4.1B | — |
8季度趋势，按日历期对齐
经营现金流REGNRNR
| Q1 26 | $1.1B | — | ||
| Q4 25 | $1.2B | $483.0M | ||
| Q3 25 | $1.6B | $1.6B | ||
| Q2 25 | $1.1B | $1.5B | ||
| Q1 25 | $1.0B | $157.8M | ||
| Q4 24 | $1.3B | $778.9M | ||
| Q3 24 | $1.3B | $1.5B | ||
| Q2 24 | $354.0M | $1.2B |
自由现金流REGNRNR
| Q1 26 | $848.3M | — | ||
| Q4 25 | $922.0M | — | ||
| Q3 25 | $1.4B | — | ||
| Q2 25 | $925.4M | — | ||
| Q1 25 | $815.8M | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | $1.0B | — | ||
| Q2 24 | $173.5M | — |
自由现金流率REGNRNR
| Q1 26 | 23.5% | — | ||
| Q4 25 | 23.7% | — | ||
| Q3 25 | 37.8% | — | ||
| Q2 25 | 25.2% | — | ||
| Q1 25 | 26.9% | — | ||
| Q4 24 | 28.1% | — | ||
| Q3 24 | 28.2% | — | ||
| Q2 24 | 4.9% | — |
资本支出强度REGNRNR
| Q1 26 | 6.4% | — | ||
| Q4 25 | 6.4% | — | ||
| Q3 25 | 5.4% | — | ||
| Q2 25 | 6.0% | — | ||
| Q1 25 | 7.6% | — | ||
| Q4 24 | 5.3% | — | ||
| Q3 24 | 6.5% | — | ||
| Q2 24 | 5.1% | — |
现金转化率REGNRNR
| Q1 26 | 1.48× | — | ||
| Q4 25 | 1.39× | 0.64× | ||
| Q3 25 | 1.11× | 1.73× | ||
| Q2 25 | 0.82× | 1.76× | ||
| Q1 25 | 1.29× | 0.93× | ||
| Q4 24 | 1.38× | — | ||
| Q3 24 | 0.96× | 1.26× | ||
| Q2 24 | 0.25× | 2.41× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
REGN
| Sanofi | $1.6B | 45% |
| Other | $507.0M | 14% |
| EYLEA - U.S | $473.0M | 13% |
| Bayer | $287.0M | 8% |
| Libtayo ® - U.S | $286.0M | 8% |
| Other revenue | $171.0M | 5% |
| Libtayo - ROW* | $152.0M | 4% |
| Praluent - U.S | $67.0M | 2% |
| Evkeeza ® - U.S | $46.0M | 1% |
| Lynozyfic ® - Global | $11.0M | 0% |
RNR
暂无分部数据
